Lurasidone in schizophrenia in adolescents: a profile of its use
Declarations
Funding The preparation of this review was not supported by any external funding.
Authorship and conflicts of interest M. Shirley is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.
Abstract
The second-generation (atypical) antipsychotic lurasidone (Latuda®) presents a useful option to consider for the treatment of schizophrenia in adolescents. As demonstrated in a 6‑week, randomised, double-blind, placebo-controlled phase 3 clinical trial, oral lurasidone provides clinically meaningful symptom improvements in adolescents with schizophrenia. Furthermore, continued improvement in symptoms is observed during longer-term treatment, based on a 2-year open-label extension study. The drug is generally well tolerated and appears to have a low propensity for weight gain and other metabolic adverse events commonly associated with second-generation antipsychotics, a potential advantage that may be particularly relevant to adolescent patients.
© Springer Nature Switzerland AG 2021
